-
26-11-2020, 10:58 AM
#18641
Junior Member
wow share price dropping quickly
-
26-11-2020, 11:05 AM
#18642
Originally Posted by psychic
I see they are also now quietly acknowledging that tests will be only reimbursed by CMS when "medically necessary"
We discussed this a few weeks ago. CMS definition:
MEDICALLY NECESSARY
Services or supplies that: are proper and needed for the diagnosis or treatment of your medical condition, are provided for the diagnosis, direct care, and treatment of your medical condition, meet the standards of good medical practice in the local area, and aren't mainly for the convenience of you or your doctor.
...
The "standards of good medical practice" are those set by the AUA
The AUA do not recommend the use of Urinary biomarkers.
So are you saying that Kaiser Permanente with 12million patients and known as a leading healthcare provider and having impeccable standards who have accepted cxBladderas a useful tool are not following the "standards of good medical practice"?
Find that pretty hard to follow.
Last edited by Minerbarejet; 26-11-2020 at 11:06 AM.
-
26-11-2020, 11:14 AM
#18643
Originally Posted by RTM
Not a current holder but still interested.
What “impressed” me at first look is t he size of the numbers...or lack of
Total Rev of 4.1mil....and that’s a 50% increase.
It’s minuscule really.
Even selling used cars we get ~150ml.
Long way to go...pleased to be out...will continue to watch with interest.
GLTAH !
The difference is that used car dealers don't buy cars for $100 and sell them for $US 760
The testing capacity of 260,000 tests per annum is also impressive. All depends now on the skill of the board and management.
-
26-11-2020, 11:21 AM
#18644
Originally Posted by Minerbarejet
So are you saying that Kaiser Permanente with 12million patients and known as a leading healthcare provider and having impeccable standards who have accepted cxBladderas a useful tool are not following the "standards of good medical practice"?
Find that pretty hard to follow.
No. What I am saying is that CMS, Kaiser, the world really, will use the tests when appropriate. Having a commercial agreement with KP does not mean they will be adopting it wholesale or replacing what is considered gold standard.
-
26-11-2020, 11:24 AM
#18645
Here in NZ 65% of the DHB's actually have it in the Clinical pathway. Yet what is the growth NZ if you strip out grants etc?
-
26-11-2020, 11:29 AM
#18646
Originally Posted by psychic
No. What I am saying is that CMS, Kaiser, the world really, will use the tests when appropriate. Having a commercial agreement with KP does not mean they will be adopting it wholesale or replacing what is considered gold standard.
The tests will be applied if it is more profitable to do so
-
26-11-2020, 12:43 PM
#18647
Originally Posted by Balance
Sp to test 65c?
-
26-11-2020, 12:58 PM
#18648
58c by Xmas.
If it wasnt for the ANZ pumping in $25M, thats where it would be now.
Last edited by Getty; 26-11-2020 at 12:59 PM.
-
26-11-2020, 01:01 PM
#18649
Originally Posted by Getty
58c by Xmas.
If it wasnt for the ANZ pumping in $25M, thats where it would be now.
Don’t think so.
Buying opportunity at 65c imo.
85c by Christmas once traders are out by next week.
Last edited by Balance; 26-11-2020 at 01:04 PM.
-
26-11-2020, 01:05 PM
#18650
For the sake of the s/holders, I hope you are right.
I took 72/3 today
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks